Himalaya Nutravedics

Himalaya Nutravedics stands at the forefront of the Nutraceutical and Ayush industry, harmonising the wisdom of Ayurveda and Nutrition with modern research and advanced technologies.

We are dedicated to discovering, developing, and delivering high quality formulations that empower healthier lives. Our commitment goes beyond manufacturing; we craft wellness solutions rooted in integrity and purity.

Here is the complete, structured step-by-step update for the Himalaya Nutravedics India IPO in formal English, with all details preserved:

1. Core Issue Details

• Issue Type: Bookbuilding Fresh Issue (BSE SME)

• Total Issue Size: 24,99,600 shares (aggregating up to ₹26.50 Crore)

• Price Band: ₹100 to ₹106 per share

• Face Value: ₹10 per share

• Post-Issue Market Cap: ₹93.35 Crore (at upper price band)

2. Key Timetable

3. Lot Size & Investment Limits

• Lot Unit Size: 1,200 Shares

• Retail Individual Investors (IND):

  • Application: 2 Lots (2,400 Shares)

  • Investment Amount: ₹2,54,400 (at upper price band)

• Small HNI (S-HNI):

  • Minimum: 3 Lots (3,600 Shares) — ₹3,81,600

  • Maximum: 7 Lots (8,400 Shares) — ₹8,90,400

• Big HNI (B-HNI):

  • Minimum: 8 Lots (9,600 Shares) — ₹10,17,600

4. Issue Reservation Breakdown

• QIB (Qualified Institutional Buyers): Not more than 50.00% of the Net Offer

• NII (Non-Institutional Investors / HNI): Not less than 15.00% of the Net Offer

• Retail Individual Investors (RII): Not less than 35.00% of the Net Offer

5. Company Financials & Valuation Indicators

Financial Highlights (₹ in Crore):

• Total Income:

  • FY24: ₹14.43 Cr

  • FY25: ₹21.00 Cr

  • FY26: ₹43.12 Cr (+105% YoY)

• Profit After Tax (PAT):

  • FY24: ₹0.43 Cr

  • FY25: ₹2.23 Cr

  • FY26: ₹7.39 Cr (+231% YoY)

• EBITDA (FY26): ₹8.10 Cr

• Net Worth (FY26): ₹16.38 Cr

• Total Borrowing (FY26): ₹5.13 Cr

Key Valuation Metrics (FY26):

• ROE: 63.87%

• ROCE: 36.41%

• PAT Margin: 17.16%

• EBITDA Margin: 18.82%

• Debt to Equity: 0.31

• P/E Ratio (Post IPO): 12.63x

• NAV: ₹26.70

• Price to Book Value: 3.97

6. Objects of the Issue

The net proceeds of ₹21.25 Crore will be allocated towards:

1. Funding Working Capital Requirements: ₹13.75 Cr

2. Business Development & Digital Marketing Activities: ₹7.50 Cr

3. General Corporate Purposes: Remaining balance

7. Shareholding Structure & Promoters

• Pre-IPO Promoter Holding: 95.14%

• Post-IPO Promoter Holding: 69.94%

• Company Promoters: Rohit Asawa, Divya Asawa, Chanda Asawa, and Rama Raju Penmatsas.

8. Company Profile & Key Strengths

• Incorporation: June 2022 (Based in Hyderabad, Telangana).

• Business Operations: Formulates, manufactures, and markets Ayurvedic and nutraceutical products across multiple dosage forms (softgels, tablets, medicated oils, liquid orals, hardgels, and protein powders).

• Geographic Reach: Market presence across 17 states and 1 union territory in India.

• Certifications: Manufacturing unit in Cherlapally holds ISO 22000:2018, ISO 9001:2015, and WHO-GMP certifications.

• Workforce: 80 employees on payroll as of April 30, 2026.

9. Key Entities Involved

• Book Running Lead Manager: Nirbhay Capital Services Pvt. Ltd.

• Registrar of the Issue: Kfin Technologies Ltd.

• Registered Address: Plot No. 101/A, Phase-III, Industrial Development Park, Cherlapally, Uppal, Hyderabad, Telangana, 500051.